INDUSTRY CITY AND SUNSET PARK — Brooklyn-based biotechnology company Cresilon Inc. uncovered a hemostatic gel technology that will make traumatic brain injuries (TBI) significantly less devastating. 

The technology, announced July 9, completed its first stage of preclinical study successfully. The gel controls bleeding and provides neuroprotection following a penetrating TBI, such as from a gunshot or shrapnel. This form of brain injury is the most severe form of TBI. 

The Cresilon Hemostatic Gel is being developed under a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) and the U.S. Department of Defense (DoD). The developers hope the gel will be useful to treat military service members and civilians, but the goal is to treat the common brain injuries caused by uncontrollable blood and trauma to the brain in combat.